2009
DOI: 10.1200/jco.2009.27.15_suppl.1089
|View full text |Cite
|
Sign up to set email alerts
|

Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer

Abstract: 1089 Background: The addition of bevacizumab (B) to paclitaxel (P) results in a significant improvement in PFS in pts with metastatic breast cancer (MBC) (Miller K, et al. New Engl J Med 2007). A randomized Phase II trial examining the efficacy and safety of adding gemcitabine (G) to the PB doublet has completed enrollment. Reported here are preliminary efficacy and safety results. Methods: This is a US, multicenter, randomized, superiority trial. Eligible pts have locally advanced or metastatic breast cancer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2010
2010
2011
2011

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…PB is used to treat metastatic breast cancer ( Table 1 ). 1-10 PB has also been used in other advanced cancers such as ovarian, lung, and melanoma. 11-13…”
Section: Indicationsmentioning
confidence: 99%
See 4 more Smart Citations
“…PB is used to treat metastatic breast cancer ( Table 1 ). 1-10 PB has also been used in other advanced cancers such as ovarian, lung, and melanoma. 11-13…”
Section: Indicationsmentioning
confidence: 99%
“…Because febrile neutropenia was reported in 0.3% to 8% of patients in the trials reviewed, 3-5,7,8 prophylactic use of colony stimulating factors is not recommended. Colony stimulating factors may be considered if a patient experiences febrile neutropenia or grade 4 neutropenia.…”
Section: Supportive Carementioning
confidence: 99%
See 3 more Smart Citations